LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 127 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,508 | -16.3% | 10,600 | 0.0% | 0.00% | -20.0% |
| Q2 2023 | $14,946 | -6.0% | 10,600 | 0.0% | 0.01% | -16.7% |
| Q1 2023 | $15,900 | +28.2% | 10,600 | 0.0% | 0.01% | +20.0% |
| Q4 2022 | $12,402 | +3.4% | 10,600 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $12,000 | -29.4% | 10,600 | 0.0% | 0.01% | -28.6% |
| Q2 2022 | $17,000 | +6.2% | 10,600 | 0.0% | 0.01% | +40.0% |
| Q1 2022 | $16,000 | -38.5% | 10,600 | 0.0% | 0.01% | -28.6% |
| Q4 2021 | $26,000 | -3.7% | 10,600 | 0.0% | 0.01% | -12.5% |
| Q3 2021 | $27,000 | -10.0% | 10,600 | 0.0% | 0.01% | 0.0% |
| Q2 2021 | $30,000 | +20.0% | 10,600 | 0.0% | 0.01% | 0.0% |
| Q1 2021 | $25,000 | +31.6% | 10,600 | 0.0% | 0.01% | +33.3% |
| Q4 2020 | $19,000 | +90.0% | 10,600 | -8.6% | 0.01% | +50.0% |
| Q2 2020 | $10,000 | +11.1% | 11,600 | 0.0% | 0.00% | -33.3% |
| Q1 2020 | $9,000 | -10.0% | 11,600 | 0.0% | 0.01% | +50.0% |
| Q4 2019 | $10,000 | -9.1% | 11,600 | 0.0% | 0.00% | -33.3% |
| Q3 2019 | $11,000 | – | 11,600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $55,198,000 | 4.16% |
| Raffles Associates | 1,930,536 | $3,050,000 | 3.32% |
| Defender Capital, LLC. | 5,131,935 | $8,108,000 | 3.18% |
| Prescott General Partners LLC | 1,851,851 | $2,926,000 | 0.20% |
| DAFNA Capital Management LLC | 140,000 | $221,000 | 0.06% |
| Laurion Capital Management LP | 2,422,367 | $3,827,000 | 0.06% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $71,000 | 0.05% |
| Fort Sheridan Advisors LLC | 78,931 | $125,000 | 0.04% |
| Long Focus Capital Management, LLC | 215,000 | $340,000 | 0.04% |
| MORGAN JESS S & CO INC | 20,000 | $32,000 | 0.03% |